Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study Phase III, Randomized, Double-dummy, Placebo Controlled, Single-center, of Regarding the Non-inferiority of the Medication BL3000, When Compared to Pantogar® Treatment of Telogen Effluvium in Women.

NCT04880889 is registered in ClinicalTrials.gov with Biolab Sanus Farmaceutica as lead sponsor.

NCT NCT04880889
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04880889 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study Phase III, Randomized, Double-dummy, Placebo Controlled, Single-center, of Regarding the Non-inferiority of the Medication BL3000, When Compared to Pantogar® Treatment of Telogen Effluvium in Women.
Lead sponsor
Biolab Sanus Farmaceutica
Phase
Phase 3
Overall status
Unknown status
Start date
January 1, 2023
Completion date
July 30, 2023
Enrollment
326 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

telogen effluvium